Biotinylated MHC Complexes Using Long Peptide Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biotinylated MHC-peptide complexes, which rely on short mimetic biotinylation peptides, may not provide optimal spacing and structural rigidity for effective epitope recognition, limiting their efficiency in detecting antigen-specific T cells and anti-HLA antibodies.
Innovation Solution
Using a naturally occurring biotinylation domain longer than 50 amino acids, such as the biotin carboxyl carrier protein (BCCP) subunit, to create biotinylated MHC complexes that maintain a rigid structure and improve epitope recognition, while allowing for efficient biotinylation and multimerization using streptavidin binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If short mimetic biotinylation peptides are used, then the MHC complexes can be produced efficiently, but the structural rigidity and spacing for epitope recognition are compromised
Solution Approach 1:
The patent changes the key parameter of biotinylation peptide length from short (mimetic) to long (natural, >50 amino acids). This parameter change simultaneously provides structural rigidity and appropriate spacing for epitope recognition while maintaining compatibility with biotinylating enzymes like BirA, thus resolving the contradiction between structural stability and production efficiency
Solution Approach 2:
The patent copies the natural biotinylation peptide sequence (such as from biotin carboxyl carrier protein) rather than using artificial mimetics. This copying approach preserves the natural structural properties including rigidity and spacing characteristics that have evolved for optimal function, while still being recognizable by biotinylating enzymes
2Ease of manufacture
If short mimetic biotinylation peptides are used, then the biotinylation process is simplified, but the recognition of epitopes by anti-MHC antibodies is reduced
Solution Approach 1:
The patent changes the biotinylation peptide length parameter to >50 amino acids, which provides sufficient spacing and structural framework for antibody recognition. The natural sequence maintains enzyme recognition sites for straightforward biotinylation, thus improving measurement precision without sacrificing ease of manufacture
Solution Approach 2:
The long biotinylation peptide acts as an intermediary structure that connects the MHC molecule to the biotin label. This intermediary provides the necessary structural rigidity and spacing to allow anti-MHC antibodies to properly access and recognize epitopes, while still serving as a effective substrate for biotinylating enzymes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of longer biotinylation domains in biotinylated MHC complexes enhances the recognition of epitopes by anti-MHC antibodies, improving the detection of antigen-specific T cells and anti-HLA antibodies, with efficient production and high biotinylation yields.
Implementation Method 1
a biotinylation peptide which can be biotinylated with a biotinylating enzyme
Implementation Method 2
coupling of MHC monomers to tetravalent streptavidin/avidin
Data Source
AI summary
The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes.